|Bid||120.85 x 1200|
|Ask||124.24 x 800|
|Day's Range||119.08 - 124.66|
|52 Week Range||86.88 - 154.24|
|Beta (5Y Monthly)||1.19|
|PE Ratio (TTM)||52.74|
|Earnings Date||Nov 03, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||164.82|
Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.
Jazz Pharmaceuticals (NASDAQ: JAZZ) hasn't given investors much good news so far in 2020. The drugmaker's first-quarter results announced in May were disappointing. Jazz stock has dropped 23% year to date.
Jazz (JAZZ) delivered earnings and revenue surprises of 9.76% and 11.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?